Table 2.

Summary of NMA/RIC and non-HLA-identical HSCT for SCD.

Ref.	Study period, n, age range (years)	Graft failure	Mean donor chimerism, myeloid/T cell compartments	Acute GVHD, II-IV	Chronic GVHD	Overall survival	Disease-free survival*
Krishnamurti et al[19]	~1999-2006, n=7, 6-18	14.3%	M: 78% (range 76-100%)	28.6%	14.3%	100%	85.7%
			T: 68.5% (range 50-90%)
Hsieh et al[20]	2004-2013, n=30, 16-65	13.3%	M: 86% (95% CI, 70-100%	0%	0%	96.7% at 3 years	87%
			T: 48%, (95% CI, 34-62%)
Horan et al [21]	2009-2013, n=14, 4-16	32%	M: 67% (95% CI, 55-80%)	14.3%	14.3%	100%	100%
			T: 96% (95% CI, 91-101%) (calculated)
Iannone et al [22]	1999-2001, n=7**, 3-20	14% primary graft failure, 86% secondary graft failure	Donor chimerism < 10% in long term follow up for all patients	14.3%	0%	100%	0%
Kamani et al [23]	~2008-2011, n=8, 7.4-16.2	62.5%	NR	25%	12.5%	87.5% at 2 years	37.5%
Dallas et al (RIC, haplo cohort) [15]	~2000-2012, n=8, 4.2-13.4	38%	Not reported	50%	37.5%	75% at 7 years	38%
Bolanos-Meade et al [24]	2006-2011, n=14 (11 haplo and 3 MRD),	21.4% overall, 43% for haplo	Unsorted: 80% T: 71% (calculated)	0%	0%	100%	64.7%

^*defined as not requiring treatment for SCD

^**6 patients with SCD, and 1 patient with thalassemia